Publication details
Metabolický syndrom a prevence kardiovaskulárních onemocnění ve stáří
| Title in English | Metabolic syndrome and prevention of cardiovascular diseases in older age |
|---|---|
| Authors | |
| Year of publication | 2014 |
| Type | Article in Periodical |
| Magazine / Source | Postgraduální medicína |
| MU Faculty or unit | |
| Citation | |
| Field | Cardiovascular diseases incl. cardiosurgery |
| Keywords | metabolic syndrome; cardiovascular risk; hypertension; type 2 diabetes mellitus |
| Description | Metabolic syndrome (MS) is considered to be one of the most significant risk factors for development of cardiovascular diseases (CVD). It is associated with a whole range of both "classical" and newly defined CVD risk factors, as well as with early symptoms of subclinical cardiovascular damage. The close relationship between various components of MS and the effects they produce when acting together are necessary to consider carefully to understand the causes and effects at play. The prevalence of MS is on the rise on a global scale, due to factors like high-calorie food, sedentary lifestyle, obesity and higher life expectancy. High prevalence of damage to the affected organs and negative prognosis have been confirmed by many prospective studies. The treatment has to be focused both on lowering the risk of CVD and on preventing the development of type 2 diabetes mellitus. The basis of the treatment acting against the mechanisms by which MS develops. This involves lifestyle adjustments meant to reduce visceral obesity, along with using substances preventing insulin resistance or weight increase. It is also important to treat the components of MS. Blood pressure control should be based on lifestyle adjustments; if medication is needed, ACE inhibitors, ATI receptor blockers for angiotensin II or calcium channel blockers and centrally acting drugs should be preferred. The views on MS have been developing over the years, the knowledge about its origins and causes is growing and therapeutic options are improving. In clinical practice, MS makes it possible to pinpoint people with higher CVD risk (including people of higher age) and enables timely intervention. |